SCHEMBL3326063

SCHEMBL3326063

CCOc1cccc(F)c1OCC1CCCNC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 7/20 0.46
HTR1A P08908 6/20 0.46
FEN1 P39748 1/20 0.46
SCN9A Q15858 1/20 0.43
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
HTR2A P28223 2/20 0.41
ADRB2 P07550 1/20 0.41
ADRA1A P35348 1/20 0.41
HTR2B P41595 1/20 0.41
PIM1 P11309 2/20 0.40
EED O75530 1/20 0.40
PIM2 Q9P1W9 1/20 0.39
IKBKB O14920 1/20 0.39
CHUK O15111 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3326057 1.00 SLC6A2 (0.46) SLC6A2HTR1AFEN1SCN9AF2
SCHEMBL3325185 0.89 HTR1A (0.47) SLC6A2HTR1AFEN1SCN9AF2
SCHEMBL3321594 0.89 HTR1A (0.47) SLC6A2HTR1AFEN1SCN9AF2
SCHEMBL3325539 0.87 FEN1 (0.46) SLC6A2HTR1AFEN1SCN9AF2
SCHEMBL3325558 0.87 FEN1 (0.46) SLC6A2HTR1AFEN1SCN9AF2
SCHEMBL3325416 0.83 SLC6A2 (0.50) SLC6A2HTR1AFEN1SLC6A4SLC6A3
SCHEMBL3328235 0.83 SLC6A2 (0.50) SLC6A2HTR1AFEN1SLC6A4SLC6A3
SCHEMBL3326206 0.83 SLC6A2 (0.57) SLC6A2HTR1ASCN9ASLC6A4SLC6A3
SCHEMBL3324885 0.83 SLC6A2 (0.57) SLC6A2HTR1ASCN9ASLC6A4SLC6A3
SCHEMBL27751579 0.81 SCN9A (0.45) SLC6A2HTR1AFEN1SCN9AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US disclosed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP disclosed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120858-A1 Piperidine Derivatives P2RX5, P2RX7, P2RX1 SLC6A2 2609/4885HTR1A 302/4885FEN1 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.